Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

LYRA

Lyra Therapeutics Inc

Nov 14 • 04:00PM ET

3.85

+0.03 0.79 %

Healthcare • Biotechnology • USA • NASD

Peers: JNJ PFE MRK GSK BMY LLY REGN AMGN VRTX ALNY

| Held by: VTI VXF DFAS

Index	-	P/E	-	EPS (ttm)	-23.78	Insider Own	8.53%	Shs Outstand	1.64M	Perf Week	-16.49%
Market Cap	6.83M	Forward P/E	-	EPS next Y	-4.76	Insider Trans	-43.92%	Shs Float	1.62M	Perf Month	-46.15%
Enterprise Value	16.16M	PEG	-	EPS next Q	-3.76	Inst Own	21.79%	Short Float	1.44%	Perf Quarter	-47.33%
Income	-32.95M	P/S	11.38	EPS this Y	82.09%	Inst Trans	1.88%	Short Ratio	0.79	Perf Half Y	-31.07%
Sales	0.60M	P/B	-	EPS next Y	62.86%	ROA	-53.81%	Short Interest	0.02M	Perf YTD	-62.69%
Book/sh	-2.63	P/C	0.31	EPS next 5Y	54.56%	ROE	-404.48%	52W High	37.50 -89.73%	Perf Year	-72.00%
Cash/sh	12.43	P/FCF	-	EPS past 3/5Y	24.62% -2.22%	ROIC	-147.30%	52W Low	3.72 3.49%	Perf 3Y	-97.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	75.25% -	Gross Margin	3.50%	Volatility	8.68% 8.22%	Perf 5Y	-99.29%
Dividend TTM	-	EV/Sales	26.93	EPS Y/Y TTM	68.97%	Oper. Margin	-5401.33%	ATR (14)	0.47	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.43	Sales Y/Y TTM	-59.21%	Profit Margin	-5491.17%	RSI (14)	21.07	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	62.68%	SMA20	-28.92%	Beta	0.03	Target Price	11.50
Payout	-	Debt/Eq	-	Sales Q/Q	-87.18%	SMA50	-38.74%	Rel Volume	1.80	Prev Close	3.82
Employees	30	LT Debt/Eq	-	Earnings	Nov 12 AMC	SMA200	-50.77%	Avg Volume	29.55K	Price	3.85
IPO	May 01, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	35.68% -87.85%	Trades		Volume	53,313	Change	0.79%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Downgrade	Jefferies	Buy → Hold	$10 → $0.50
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $2
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy	$15
Aug-31-23	Initiated	H.C. Wainwright	Buy	$12
May-24-22	Initiated	Cantor Fitzgerald	Overweight	$15
May-26-20	Initiated	William Blair	Outperform
May-26-20	Initiated	Jefferies	Buy	$24
May-26-20	Initiated	BTIG Research	Buy	$28
May-26-20	Initiated	BofA/Merrill	Buy	$21

Show Previous Ratings

Nov-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.49%
04:01PM	Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-25 05:45PM	Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-06-25 09:15AM	Dentsply International (XRAY) Lags Q3 Earnings Estimates (Zacks) -12.81%
Nov-04-25 09:15AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.30%
07:00AM	Loading…
Oct-06-25 07:00AM	Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study (GlobeNewswire) +15.57%
Aug-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.00%
04:01PM	Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-25 08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jun-27-25 08:00AM	Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -31.91%
Jun-12-25 12:00PM	Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why (Zacks) -12.22%
Jun-05-25 12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks) +11.00%
Jun-02-25 12:08PM	Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win (GuruFocus.com) +310.75%
07:00AM	Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) (GlobeNewswire)
May-07-25 07:00AM	Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 (GlobeNewswire)
05:20PM	Loading…
May-06-25 05:20PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-31-25 06:55PM	Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -9.07%
Mar-13-25 04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-09-25 12:00PM	Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-12-24 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -28.11%
04:01PM	Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-15-24 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Sep-27-24 07:00AM	Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings (GlobeNewswire) +10.07%
Aug-14-24 09:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:30PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-15-24 11:35AM	Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1? (Insider Monkey)
May-21-24 10:31AM	Lyra Therapeutics Reduces Workforce to Extend Cash Runway (MT Newswires)
09:14AM	Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital (GlobeNewswire)
09:54AM	Loading…
May-07-24 09:54AM	Target upgraded, CVS downgraded: Wall Street's top analyst calls (The Fly) -19.46%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:38AM	--HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy (MT Newswires)
May-06-24 12:08PM	DJT Stock: Trump Media Fires Accounting Firm, Hires Replacement After SEC Charges (InvestorPlace) -87.06%
11:32AM	ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range? (InvestorPlace)
11:07AM	Warren Buffett Just Gave Up on Paramount (PARA) Stock (InvestorPlace)
10:51AM	Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today? (InvestorPlace)
08:52AM	Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell (MT Newswires)
07:59AM	Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Apr-30-24 09:56PM	LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) +9.09%
05:30PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:04PM	Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-24 04:51PM	Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.70%
Mar-28-24 07:08AM	Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock? (Zacks)
Mar-25-24 08:50AM	Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-23-24 05:31AM	Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections (GuruFocus.com)
Mar-22-24 09:55AM	Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High? (Zacks)
Mar-21-24 10:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-24 08:50AM	Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going (Zacks)
Mar-01-24 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.17%
Feb-26-24 03:58AM	Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength? (Zacks)
Feb-21-24 08:50AM	Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength (Zacks)
Jan-17-24 08:50AM	What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing' (Zacks)
Nov-07-23 04:01PM	Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 07:00AM	Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer (GlobeNewswire)
Sep-13-23 01:22PM	Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up (Zacks)
Sep-12-23 07:00AM	Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery (GlobeNewswire) +7.48%
Sep-06-23 08:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Aug-08-23 05:50PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:30AM	Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference (GlobeNewswire)
Jun-02-23 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
07:30AM	Lyra Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Lyra Therapeutics Announces Closing of $50.0 Million Private Placement (GlobeNewswire) +5.06%
May-26-23 07:57AM	Lyra Therapeutics Announces $50.0 Million Private Placement (GlobeNewswire) +6.58%
May-14-23 08:19AM	Lyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-12-23 08:15AM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:01PM	Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-29-23 08:19AM	Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) biggest owners are retail investors who got richer after stock soared 18% last week (Simply Wall St.)
Apr-25-23 07:59AM	Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Mar-29-23 04:06PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-20-23 01:11PM	Estimating The Intrinsic Value Of Lyra Therapeutics, Inc. (NASDAQ:LYRA) (Simply Wall St.)
Mar-01-23 05:21AM	Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks) -5.04%
Feb-28-23 05:17AM	Lyra Therapeutics, Inc. (NASDAQ:LYRA) insiders placed bullish bets worth US$1.5m in the last 12 months (Simply Wall St.)
Feb-27-23 07:59AM	Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer (GlobeNewswire)
Feb-07-23 01:23PM	Here's Why We're Watching Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Situation (Simply Wall St.)
Feb-06-23 07:56AM	Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients (GlobeNewswire)
Jan-17-23 06:42PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-20-22 08:52AM	Further weakness as Lyra Therapeutics (NASDAQ:LYRA) drops 15% this week, taking one-year losses to 49% (Simply Wall St.)
Nov-09-22 08:00AM	Lyra Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -15.52%
Nov-08-22 05:45PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 06:11AM	Bullish insiders at Lyra Therapeutics, Inc. (NASDAQ:LYRA) loaded up on US$1.5m of stock earlier this year (Simply Wall St.)
Sep-13-22 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study (PR Newswire)
Sep-10-22 08:00AM	LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting (PR Newswire)
Sep-08-22 07:00AM	Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients (PR Newswire)
Sep-06-22 07:00AM	Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022 (PR Newswire)
Aug-31-22 02:08PM	We're Hopeful That Lyra Therapeutics (NASDAQ:LYRA) Will Use Its Cash Wisely (Simply Wall St.)
Aug-29-22 07:00AM	Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR210 in Two Oral Presentations at ARS Annual Meeting (PR Newswire) +8.52%
Aug-11-22 08:05AM	Are Institutions Heavily Invested In Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) Shares? (Simply Wall St.)
Aug-09-22 08:25AM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-22 09:40AM	Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-22 09:21AM	Increasing losses over year doesn't faze investors as stock rallies 12% this past week (Simply Wall St.)
Jul-05-22 07:00AM	Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022 (PR Newswire)

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 13 '25	Sale	3.90	31,810	124,062	14,026	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 12 '25	Sale	4.06	8,745	35,499	17,239	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 11 '25	Sale	4.31	5,320	22,954	18,122	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 06 '25	Sale	5.18	32,149	166,529	22,521	Nov 10 05:08 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 07 '25	Sale	4.75	19,739	93,695	20,528	Nov 10 05:08 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 10 '25	Sale	4.54	18,502	83,995	18,659	Nov 10 05:08 PM
Palasis Maria	Officer	Oct 14 '25	Proposed Sale	7.23	537	3,881		Oct 14 03:09 PM
Palasis Maria	President & CEO	Jul 10 '25	Sale	8.91	1,565	13,944	1,098,435	Jul 14 09:27 PM
Cavalier Jason	Chief Financial Officer	Jul 10 '25	Sale	8.91	684	6,094	519,316	Jul 14 09:27 PM
Palasis Maria	Officer	Jul 10 '25	Proposed Sale	8.91	1,565	13,945		Jul 10 04:05 PM
Waksal Harlan	Officer	Apr 25 '25	Proposed Sale	0.10	145,370	14,930		Apr 25 03:41 PM
Palasis Maria	Officer	Apr 09 '25	Proposed Sale	0.09	39,567	3,545		Apr 09 03:44 PM

Open in Screener

OBIO

Orchestra BioMed Holdings Inc

Nov 14 • 04:00PM ET

3.94

-0.24 -5.74 %

Healthcare • Biotechnology • USA • NASD

OBIO Orchestra BioMed Holdings Inc daily Stock Chart

Peers: BSX ABT MDT JNJ STXS SYK IART STE GMED PEN

| Held by: VTI VXF SCHA IWC AVSC MSSM DFAC

Index	-	P/E	-	EPS (ttm)	-1.82	Insider Own	18.65%	Shs Outstand	56.46M	Perf Week	3.41%
Market Cap	222.47M	Forward P/E	-	EPS next Y	-1.57	Insider Trans	7.50%	Shs Float	45.93M	Perf Month	7.07%
Enterprise Value	158.85M	PEG	-	EPS next Q	-0.38	Inst Own	38.18%	Short Float	2.15%	Perf Quarter	49.81%
Income	-75.10M	P/S	78.89	EPS this Y	-5.65%	Inst Trans	2.31%	Short Ratio	3.27	Perf Half Y	35.86%
Sales	2.82M	P/B	5.09	EPS next Y	10.34%	ROA	-83.39%	Short Interest	0.99M	Perf YTD	-1.50%
Book/sh	0.77	P/C	2.32	EPS next 5Y	12.29%	ROE	-166.97%	52W High	6.50 -39.38%	Perf Year	-30.39%
Cash/sh	1.70	P/FCF	-	EPS past 3/5Y	-347.45% -273.68%	ROIC	-99.81%	52W Low	2.20 79.09%	Perf 3Y	-60.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	82.82%	Volatility	9.07% 9.19%	Perf 5Y	-64.82%
Dividend TTM	-	EV/Sales	56.33	EPS Y/Y TTM	-14.32%	Oper. Margin	-2669.91%	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.72	Sales Y/Y TTM	6.46%	Profit Margin	-2665.05%	RSI (14)	55.09	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	4.73	EPS Q/Q	2.66%	SMA20	1.00%	Beta	0.63	Target Price	13.60
Payout	-	Debt/Eq	0.74	Sales Q/Q	-12.77%	SMA50	22.68%	Rel Volume	0.66	Prev Close	4.18
Employees	70	LT Debt/Eq	0.72	Earnings	Nov 10 AMC	SMA200	17.51%	Avg Volume	302.76K	Price	3.94
IPO	Aug 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-0.65% 16.13%	Trades		Volume	200,240	Change	-5.74%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Downgrade	BTIG Research	Buy → Neutral
Mar-20-25	Initiated	BTIG Research	Buy	$12
Jan-02-25	Initiated	Barclays	Overweight	$16
Aug-22-24	Initiated	H.C. Wainwright	Buy	$14
Jul-25-24	Initiated	B. Riley Securities	Buy	$15
Jan-19-24	Initiated	Jefferies	Buy	$14
Feb-24-23	Initiated	Piper Sandler	Overweight	$15
Feb-07-23	Initiated	Chardan Capital Markets	Buy	$20

Nov-11-25 09:00AM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) +8.47%
07:31AM	What To Expect From Orchestra BioMed Holdings Inc (OBIO) Q3 2025 Earnings (GuruFocus.com)
Nov-10-25 05:30PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:10PM	Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
10:00AM	Loading…
Nov-04-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.32%
Nov-03-25 08:00AM	Orchestra BioMed to Host Business Update Call on November 12, 2025 (GlobeNewswire)
Oct-28-25 08:00AM	Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements (GlobeNewswire)
Oct-27-25 09:00AM	Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial (GlobeNewswire)
Oct-09-25 08:00AM	Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit (GlobeNewswire)
Sep-04-25 05:00PM	Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout (GlobeNewswire)
Aug-26-25 07:30AM	Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology (GlobeNewswire) +15.38%
Aug-14-25 08:00AM	Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction (GlobeNewswire)
Aug-13-25 08:00AM	Campbellford Memorial Hospitals New Homecare Program Frees up 14.5 Hospital Bed-Days Per Patient Through a Partnership With Gotcare and OBIO® (Business Wire)
Aug-12-25 03:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +7.94%
08:14AM	Loading…
08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-08-25 07:00AM	Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Aug-04-25 05:55PM	CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +9.84%
Aug-01-25 07:59AM	Orchestra BioMed Announces Pricing of $40 Million Public Offering (GlobeNewswire) -20.26%
Jul-31-25 04:02PM	Orchestra BioMed Announces Proposed Public Offering (GlobeNewswire)
04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-16-25 08:00AM	OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets (Business Wire) +7.88%
Jun-18-25 09:30AM	Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 (GlobeNewswire) -11.01%
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-12-25 05:40PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.94%
04:28PM	Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones (GlobeNewswire)
May-07-25 08:30AM	Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure (GlobeNewswire)
May-06-25 05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.47%
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -6.57%
09:00AM	Loading…
Apr-29-25 09:00AM	Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon (GlobeNewswire)
Apr-28-25 04:30PM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) -6.12%
Apr-23-25 09:00AM	Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting (GlobeNewswire)
Apr-22-25 07:00AM	Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy (GlobeNewswire)
Mar-31-25 07:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -24.30%
04:21PM	Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update (GlobeNewswire)
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-20-25 08:00AM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire) -8.77%
Feb-18-25 08:00AM	Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board (GlobeNewswire)
Feb-12-25 10:43AM	Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference (GlobeNewswire)
Feb-05-25 08:00AM	Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors (GlobeNewswire)
Dec-09-24 07:00AM	Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting (GlobeNewswire) +9.54%
Nov-26-24 04:05PM	Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.67% +7.24%
04:12PM	Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-24 08:00AM	Orchestra BioMed to Participate in Jefferies London Healthcare Conference (GlobeNewswire) -5.50%
Aug-12-24 05:35PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-24 09:35AM	Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.55%
Aug-01-24 10:01AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -7.18%
Jul-30-24 08:00AM	Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors (GlobeNewswire)
Jul-26-24 12:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know (Zacks) -6.70%
09:55AM	Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade (Zacks)
Jul-23-24 09:00AM	Precision Neuroscience Expands Executive Team as Brain Computer Interface Industry Rapidly Advances (GlobeNewswire)
Jun-24-24 08:07AM	Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar? (Zacks) +9.02%
Jun-04-24 08:00AM	Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire) +10.64%
Jun-03-24 12:00PM	All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy (Zacks)
09:55AM	Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect? (Zacks)
May-22-24 08:43AM	Orchestra BioMed to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 09:53PM	OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +13.04%
06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:58PM	Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-30-24 08:30AM	Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents (GlobeNewswire)
08:00AM	Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire)
Mar-27-24 04:17PM	Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-26-24 08:00AM	Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors (GlobeNewswire) +5.20%
Mar-13-24 08:00AM	Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 08:00AM	Orchestra BioMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.62%
Mar-06-24 08:37AM	Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients (GlobeNewswire)
Feb-26-24 08:00AM	Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years (GlobeNewswire)
Feb-16-24 09:13AM	Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season (Zacks) -8.45%
Jan-08-24 07:30AM	Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients (GlobeNewswire) +9.38%
Nov-13-23 04:21PM	Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +14.61% +13.08%
Nov-09-23 04:42PM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey)
Sep-22-23 11:27AM	Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline (American City Business Journals)
Sep-19-23 02:37PM	Rebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football Coach (TheStreet.com) +27.61%
07:30AM	Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients (GlobeNewswire)
Sep-06-23 05:00PM	Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors (GlobeNewswire) -7.74%
Aug-10-23 04:34PM	Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.05%
Aug-08-23 08:30AM	Orchestra BioMed Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon in Patients with Coronary In-Stent Restenosis (GlobeNewswire)
Jul-27-23 09:47AM	Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28% (Simply Wall St.) -14.00%
Jun-28-23 02:16PM	Why Shares of Orchestra BioMed Holdings Jumped Wednesday (Motley Fool) +24.85%
Jun-26-23 08:00AM	Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes (GlobeNewswire) -9.81%
Jun-07-23 08:30AM	Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer (GlobeNewswire) -6.42%
Jun-01-23 08:00AM	Orchestra BioMed to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.93%
May-12-23 09:15AM	Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-11-23 05:39AM	3 Stocks That Already Doubled in 2023 and Could Keep Climbing (Motley Fool) +10.12%
Mar-27-23 06:05AM	Orchestra BioMed Holdings Full Year 2022 Earnings: US$14.60 loss per share (vs US$10.90 loss in FY 2021) (Simply Wall St.)
Mar-24-23 03:52PM	Why Shares of Orchestra BioMed Jumped This Week (Motley Fool)
Mar-07-23 08:00AM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire) -6.77%
Feb-24-23 08:00AM	Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT and Virtue® SAB at CRT 2023 (GlobeNewswire)
Feb-07-23 08:00AM	Orchestra BioMed Strengthens Senior Leadership Team (GlobeNewswire)

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded by David P. Hochman on May 25, 2020 and is headquartered in New Hope, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aryeh Jason	Director	Sep 19 '25	Buy	2.45	1,000	2,450	108,482	Sep 19 06:57 PM
Fain Eric S	Director	Aug 25 '25	Buy	2.61	5,760	15,034	71,709	Aug 25 07:04 PM
Sherman Darren	See Remarks	Aug 25 '25	Buy	2.62	3,000	7,860	926,837	Aug 25 07:04 PM
Hochman David P	See Remarks	Aug 21 '25	Buy	2.49	6,000	14,940	651,460	Aug 25 07:03 PM
Taylor Andrew Lawrence	Chief Financial Officer	Aug 25 '25	Buy	2.55	2,000	5,100	482,788	Aug 25 07:01 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Aug 01 '25	Buy	2.75	700,000	1,925,000	5,292,556	Aug 05 10:46 AM
Hochman David P	See Remarks	Aug 04 '25	Buy	2.75	20,000	55,000	349,331	Aug 04 06:16 PM
Fain Eric S	Director	Jun 26 '25	Sale	3.05	2,683	8,183	50,949	Jun 27 05:10 PM
Fain Eric S	Director	Jun 26 '25	Proposed Sale	3.05	2,683	8,194		Jun 26 03:11 PM
RTW INVESTMENTS, LP	10% Owner	Apr 30 '25	Buy	2.99	49,900	149,201	8,306,063	May 01 08:18 AM
RTW INVESTMENTS, LP	10% Owner	Apr 29 '25	Buy	2.53	50,000	126,500	8,256,163	Apr 29 05:16 PM
Aryeh Jason	Director	Dec 27 '24	Option Exercise	4.30	11,700	50,310	80,060	Dec 30 06:09 PM
Hochman David P	See Remarks	Dec 23 '24	Buy	4.66	4,000	18,640	579,498	Dec 26 05:46 PM
Taylor Andrew Lawrence	Chief Financial Officer	Dec 19 '24	Buy	4.83	1,000	4,830	344,960	Dec 20 08:30 AM
Hochman David P	See Remarks	Dec 18 '24	Buy	4.91	5,000	24,550	575,498	Dec 19 08:30 AM

Open in Screener

ACRV

Acrivon Therapeutics Inc

Nov 14 • 04:00PM ET

2.24

+0.17 8.21 %

Healthcare • Biotechnology • USA • NASD

ACRV Acrivon Therapeutics Inc daily Stock Chart

Peers: BMRN VRTX REGN AMGN GILD BIIB EXEL INCY NBIX IONS

| Held by: VTI IBB VXF IWC BIB IBBQ CHNA

Index	-	P/E	-	EPS (ttm)	-2.13	Insider Own	28.78%	Shs Outstand	31.55M	Perf Week	19.15%
Market Cap	70.68M	Forward P/E	-	EPS next Y	-1.99	Insider Trans	0.00%	Shs Float	22.47M	Perf Month	19.79%
Enterprise Value	-55.58M	PEG	-	EPS next Q	-0.51	Inst Own	50.96%	Short Float	7.67%	Perf Quarter	61.15%
Income	-81.75M	P/S	-	EPS this Y	10.92%	Inst Trans	6.41%	Short Ratio	1.08	Perf Half Y	94.78%
Sales	0.00M	P/B	0.55	EPS next Y	6.03%	ROA	-45.42%	Short Interest	1.72M	Perf YTD	-62.79%
Book/sh	4.08	P/C	0.55	EPS next 5Y	6.36%	ROE	-50.23%	52W High	8.35 -73.17%	Perf Year	-73.30%
Cash/sh	4.10	P/FCF	-	EPS past 3/5Y	-45.20% -74.96%	ROIC	-62.69%	52W Low	1.05 113.33%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.67% 8.90%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	21.17%	Oper. Margin	-	ATR (14)	0.19	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.75	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.50	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	8.75	EPS Q/Q	19.70%	SMA20	9.29%	Beta	1.77	Target Price	11.17
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	20.65%	Rel Volume	0.74	Prev Close	2.07
Employees	78	LT Debt/Eq	0.01	Earnings	Nov 13 AMC	SMA200	-1.20%	Avg Volume	1.60M	Price	2.24
IPO	Nov 15, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	20.49% -	Trades		Volume	1,185,201	Change	8.21%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-25	Resumed	Piper Sandler	Overweight	$6
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$16
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform	$14
Dec-15-23	Resumed	Jefferies	Buy	$17 → $12
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform	$25
May-08-23	Initiated	BMO Capital Markets	Outperform	$25
Apr-27-23	Initiated	Ladenburg Thalmann	Buy	$22
Apr-20-23	Initiated	H.C. Wainwright	Buy	$24
Dec-12-22	Initiated	Piper Sandler	Overweight	$25
Dec-12-22	Initiated	Jefferies	Buy	$17
Dec-12-22	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-13-25 04:10PM	Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -9.21% +8.21%
Nov-02-25 05:05AM	Analysts Predict Up to 550% Rally for These 2 Strong Buy Penny Stocks (TipRanks)
Oct-22-25 04:15PM	Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference (GlobeNewswire)
Oct-01-25 04:30PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-25 04:15PM	Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) +6.11%
12:30PM	Loading…
May-17-25 12:30PM	Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch (TipRanks)
May-14-25 04:10PM	Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-05-25 09:55AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-28-25 12:23PM	Can Humana Beat Q1 Earnings Estimates on Growing Premiums? (Zacks) -5.49%
Apr-25-25 08:00AM	Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 (GlobeNewswire) -17.59%
Apr-24-25 11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
01:28PM	Can Centene Beat Q1 Earnings Estimates on Growing Premiums? (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks) +6.28%
Apr-14-25 09:35AM	Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) (Zacks) -7.41%
04:05PM	Loading…
Apr-07-25 04:05PM	Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer (GlobeNewswire) -7.95%
Mar-28-25 12:00PM	Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know (Zacks) -11.11%
09:35AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks (Zacks)
Mar-27-25 05:44PM	Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-19-25 08:00AM	Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates (GlobeNewswire)
Feb-06-25 08:16AM	Acrivon Therapeutics announces FDA granted BDD for ACR-368 (TipRanks) -6.60%
04:54AM	FDA grants breakthrough designation for Acrivons endometrial cancer assay (Medical Device Network)
Feb-05-25 03:45PM	Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status (Insider Monkey) +17.94%
08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer (GlobeNewswire)
Nov-13-24 07:00AM	Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.48%
Oct-17-24 08:00AM	Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium (GlobeNewswire)
Oct-16-24 04:00PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-24 08:28AM	Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline (TipRanks)
Oct-11-24 08:00AM	Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity (GlobeNewswire)
Sep-14-24 03:10AM	Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis (GlobeNewswire)
08:00AM	Loading…
Sep-10-24 08:00AM	Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire) +8.61%
Sep-09-24 07:00AM	Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316 (GlobeNewswire)
Aug-15-24 09:40AM	Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? (Zacks)
Aug-13-24 08:00AM	Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-21-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year? (Zacks)
May-29-24 08:00AM	Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 09:47AM	Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock (Zacks)
May-20-24 09:40AM	Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year? (Zacks)
May-14-24 01:54PM	ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-10-24 08:50AM	Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? (Zacks) +7.74%
Apr-29-24 07:08AM	Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral (MT Newswires) +18.20%
Apr-24-24 04:01PM	Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event (GlobeNewswire) -10.84%
Apr-16-24 08:01PM	Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire) +9.19%
Apr-10-24 08:00AM	Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM	ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM	Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
Mar-30-24 05:31AM	Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM	ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 (GlobeNewswire)
Mar-04-24 08:00AM	Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors (GlobeNewswire) -11.40%
Feb-27-24 08:00AM	Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +22.07%
Feb-08-24 08:00AM	Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magov evi -Liebisch, Ph.D., J.D., to Board of Directors (GlobeNewswire)
Feb-06-24 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-24 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.31%
Jan-04-24 08:00AM	Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.63%
Jan-03-24 08:00AM	Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer (GlobeNewswire)
Nov-21-23 08:00AM	Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference (GlobeNewswire) -9.02%
08:00AM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:01AM	Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -19.19%
Oct-16-23 08:00AM	Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-28-23 04:05PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-23 04:32PM	Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-05-23 04:05PM	Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivons AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies (GlobeNewswire)
Aug-30-23 08:00AM	Acrivon Therapeutics to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-17-23 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-23 07:00AM	Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +6.81%
Aug-08-23 12:38PM	Q2 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-20-23 08:00AM	Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs (GlobeNewswire)
Jun-29-23 04:49PM	7 Up-and-Coming Stocks to Buy for the Next Decade (InvestorPlace)
Jun-22-23 04:00PM	Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors (GlobeNewswire) +5.98%
Jun-02-23 08:00AM	Acrivon Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 10:43AM	Q1 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.77%
08:00AM	Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer (GlobeNewswire)
May-07-23 08:17AM	We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-25-23 08:00AM	Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-24-23 08:00AM	Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference (GlobeNewswire)
Mar-28-23 08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-06-23 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 08:00AM	Acrivon Therapeutics to Participate on a Panel at Cowens 43rd Annual Health Care Conference (GlobeNewswire) +23.94%
Feb-15-23 05:40AM	Acrivon Therapeutics, Inc. (NASDAQ:ACRV) insider upped their holding earlier this year (Simply Wall St.)
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-22-23 03:31PM	13 Cheap New Stocks To Buy (Insider Monkey)
Nov-14-22 10:16PM	Acrivon Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 30 '25	Sale	1.41	437,881	617,412	3,403,025	May 01 07:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 01 '25	Sale	1.34	298,886	400,507	3,104,139	May 01 07:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 25 '25	Sale	1.95	1,054,669	2,056,605	4,306,189	Apr 29 07:26 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 29 '25	Sale	1.41	250,000	352,500	3,840,906	Apr 29 07:26 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 28 '25	Sale	1.56	215,283	335,841	4,090,906	Apr 29 07:26 PM

Open in Screener

ALDX

Aldeyra Therapeutics Inc

Nov 14 • 04:00PM ET

5.05

+0.03 0.60 %

Healthcare • Biotechnology • USA • NASD

ALDX Aldeyra Therapeutics Inc daily Stock Chart

Peers: NBIX IONS XOMA PRTA CRBP ITCI BHVN AUPH ACAD RIGL

| Held by: VTI IWM VXF IWO VTWO VHT IWC VFMO DFAS ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.72	Insider Own	3.25%	Shs Outstand	60.16M	Perf Week	7.68%
Market Cap	303.82M	Forward P/E	20.75	EPS next Y	0.24	Insider Trans	-0.99%	Shs Float	58.15M	Perf Month	-6.31%
Enterprise Value	244.06M	PEG	-	EPS next Q	-0.14	Inst Own	59.97%	Short Float	9.12%	Perf Quarter	-7.17%
Income	-43.19M	P/S	-	EPS this Y	31.49%	Inst Trans	5.15%	Short Ratio	7.32	Perf Half Y	133.80%
Sales	0.00M	P/B	6.17	EPS next Y	137.80%	ROA	-44.27%	Short Interest	5.30M	Perf YTD	1.20%
Book/sh	0.82	P/C	4.03	EPS next 5Y	-	ROE	-64.31%	52W High	7.20 -29.86%	Perf Year	6.20%
Cash/sh	1.25	P/FCF	-	EPS past 3/5Y	4.24% 15.99%	ROIC	-87.58%	52W Low	1.14 342.98%	Perf 3Y	-2.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.89% 5.50%	Perf 5Y	-24.17%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	4.23%	Oper. Margin	-	ATR (14)	0.28	Perf 10Y	-31.34%
Dividend Ex-Date	-	Quick Ratio	2.68	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.17	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.68	EPS Q/Q	49.63%	SMA20	-1.36%	Beta	0.83	Target Price	9.67
Payout	-	Debt/Eq	0.32	Sales Q/Q	-	SMA50	-3.54%	Rel Volume	0.80	Prev Close	5.02
Employees	9	LT Debt/Eq	0.00	Earnings	Aug 08	SMA200	9.08%	Avg Volume	724.06K	Price	5.05
IPO	May 02, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	33.12% -	Trades		Volume	579,034	Change	0.60%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-03-24	Upgrade	Oppenheimer	Perform → Outperform	$10
Apr-02-24	Resumed	H.C. Wainwright	Buy	$10
Apr-27-22	Resumed	H.C. Wainwright	Buy	$15
Feb-08-21	Initiated	H.C. Wainwright	Buy	$26
Dec-16-20	Initiated	Berenberg	Buy	$32
Oct-30-20	Initiated	Jefferies	Buy	$24
Oct-16-20	Initiated	BTIG Research	Buy	$29
Sep-22-20	Initiated	Alliance Global Partners	Buy	$32
May-12-20	Initiated	Oppenheimer	Outperform	$12
Dec-04-18	Initiated	Citigroup	Buy	$23
Sep-26-18	Reiterated	Cantor Fitzgerald	Overweight	$23 → $30
Sep-13-18	Initiated	Janney	Buy
Jan-26-18	Initiated	Seaport Global Securities	Buy	$13
Sep-26-16	Initiated	H.C. Wainwright	Buy	$18
Jul-01-16	Initiated	Stifel	Buy	$16
Jul-01-15	Initiated	Canaccord Genuity	Buy	$16
Mar-25-15	Initiated	Chardan Capital Markets	Buy	$16
Mar-20-15	Reiterated	H.C. Wainwright	Buy	$13 → $14
Nov-18-14	Initiated	H.C. Wainwright	Buy	$13
Jun-19-14	Initiated	Aegis Capital	Buy	$35

Show Previous Ratings

Nov-13-25 07:00AM	Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast (Business Wire) -5.28%
Nov-11-25 07:01AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (Business Wire)
Nov-06-25 07:00AM	Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET (Business Wire)
Oct-29-25 08:16AM	Aldeyra reshuffles pipeline, culling asset despite Phase II success (Clinical Trials Arena)
Oct-28-25 07:01AM	Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules (Business Wire)
07:01AM	Loading…
Sep-03-25 07:01AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-28-25 07:01AM	Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma (Business Wire)
Aug-23-25 04:20AM	JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 (Insider Monkey)
Aug-19-25 07:01AM	Aldeyra Therapeutics Receives Fast Track Designation for ADX-2191 for the Treatment of Retinitis Pigmentosa (Business Wire)
Aug-06-25 07:01AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (Business Wire)
Jul-24-25 07:00AM	Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa (Business Wire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-15-25 12:00PM	Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Loading…
09:40AM	Are Medical Stocks Lagging Amgen (AMGN) This Year? (Zacks)
Jun-26-25 07:00AM	Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma (Business Wire) +10.26%
Jun-17-25 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
May-29-25 07:01AM	Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference (Business Wire)
May-05-25 06:34PM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission (Business Wire) -22.22%
04:00PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap (Business Wire)
Apr-29-25 11:42AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-28-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-24-25 01:57PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire) +9.50%
Apr-21-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
10:52AM	Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity (Seeking Alpha)
08:49AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-18-25 02:52PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
11:23AM	ALDX INVESTOR NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified to Contact BFA Law About How to Potentially Recover Losses (Newsfile)
Apr-17-25 07:00AM	Aldeyra Therapeutics Appoints Chip Clark to Board of Directors (Business Wire) +8.96%
05:23PM	Loading…
Apr-16-25 05:23PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire) -8.64%
Apr-15-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-11-25 01:26PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
07:43AM	ALDX STOCK NOTIFICATION: Did Aldeyra Therapeutics, Inc. Violate the Securities Laws? Investors are Notified to Contact BFA Law (NASDAQ:ALDX) (GlobeNewswire)
Apr-10-25 09:30AM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman (PR Newswire)
Apr-09-25 05:00PM	Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman (GlobeNewswire)
Apr-08-25 04:51AM	After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy (Seeking Alpha)
03:08AM	ALDX SECURITIES NOTIFICATION: Aldeyra Therapeutics, Inc. Investors that Suffered Losses are Notified to Contact BFA Law (Newsfile)
Apr-06-25 07:08AM	ALDX SECURITIES NOTICE: Aldeyra Therapeutics, Inc. Investors with Losses are Notified to Contact BFA Law as they may have been Affected by Securities Violations (Newsfile)
Apr-03-25 10:24AM	Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter (Investopedia) -73.33%
08:00AM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease (Business Wire)
Mar-10-25 07:00AM	Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference (Business Wire)
Feb-05-25 03:24AM	Aldeyra Therapeutics, Inc. (ALDX) Notice: Grabar Law Office Is Investigating Claims for Long-Term Shareholders (Newsfile) +6.73%
Feb-04-25 07:00AM	Aldeyra Therapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-20-25 03:28PM	Is Aldeyra Therapeutics (ALDX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-09-24 10:05AM	Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock? (Zacks)
Dec-02-24 07:00AM	Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-18-24 07:00AM	Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement (Business Wire) +11.64%
Nov-14-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Oct-31-24 07:00AM	Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting (Business Wire)
Oct-03-24 07:00AM	Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Sep-05-24 07:00AM	Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-30-24 10:38AM	Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory (Insider Monkey) +7.07%
Aug-09-24 06:32AM	Aldeyras Phase III clinical trial of Reproxalap meets primary endpoint (Clinical Trials Arena) +21.72%
Aug-08-24 07:00AM	Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap (Business Wire) +28.53%
Aug-07-24 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap (Business Wire) -5.23%
Jun-20-24 07:00AM	Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable (Business Wire) -6.47%
Jun-14-24 06:32AM	Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial (Clinical Trials Arena)
Jun-13-24 07:00AM	Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease (Business Wire)
Jun-12-24 07:00AM	Aldeyra Therapeutics to Host Investor Roundtable Q&A (Business Wire)
May-29-24 07:00AM	Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year? (Zacks) +12.70%
May-08-24 03:12PM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Dry Eye Chamber Study (MT Newswires)
07:00AM	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease (Business Wire)
May-03-24 08:52AM	ALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
Apr-25-24 07:00AM	Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day (Business Wire)
Apr-22-24 09:40AM	Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-18-24 07:00AM	Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024 (Business Wire)
Apr-06-24 06:37AM	Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why (Zacks)
Apr-04-24 12:36PM	Health Care Roundup: Market Talk (The Wall Street Journal) +12.89%
Apr-03-24 02:58PM	Aldeyra's Dry Eye Disease Drug May Be on Path for FDA Approval (Barrons.com) +16.90%
Mar-28-24 07:00AM	Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease (Business Wire) +6.17%
Mar-27-24 01:21PM	Notice to Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors (Newsfile) +5.48%
Mar-13-24 02:33AM	Aldeyra Therapeutics Inc President and CEO Todd Brady Sells Company Shares (GuruFocus.com)
Mar-06-24 09:40AM	Here's Why You Should Invest in Aldeyra (ALDX) Stock Now (Zacks)
Feb-06-24 07:00AM	Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +7.05%
Jan-04-24 07:00AM	Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases (Business Wire)
Dec-19-23 07:27AM	UPDATE 1-Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study (Reuters) +18.58%
07:05AM	Aldeyra Therapeutics' eczema drug succeeds in mid-stage study (Reuters)
07:00AM	Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX629 in Patients with Atopic Dermatitis (Business Wire)
Dec-18-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis (Business Wire)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Dec-05-23 09:00AM	Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings? (Zacks)
Nov-27-23 04:07PM	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease (Business Wire)
Nov-01-23 10:34AM	Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? (InvestorPlace) +48.54%
07:05AM	Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap (Business Wire)
Oct-18-23 08:30AM	Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More (Zacks) -5.98%
Oct-17-23 10:13AM	Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback (Zacks)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Jul-20-23 09:55AM	Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jul-06-23 07:00AM	Aldeyra Therapeutics to Participate in SVB Securities Therapeutics Forum (Business Wire)
Jun-29-23 07:00AM	Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX2191 in Patients with Retinitis Pigmentosa (Business Wire)
05:20AM	The Petri Dish: Startup behind VR treatments gets $16M, Aldeyra notches midstage trial win (American City Business Journals)
Jun-28-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis Pigmentosa (Business Wire)
Jun-27-23 12:03PM	Aldeyra Therapeutics' Chronic Cough Potential Shows Significant Reduction In Cough Frequency Versus Placebo (Benzinga)
07:00AM	Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX629 in Patients With Chronic Cough (Business Wire)
Jun-26-23 04:01PM	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX629 in Patients with Chronic Cough (Business Wire) +5.63%
Jun-23-23 07:00AM	Aldeyra Therapeutics to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -8.26%
Jun-21-23 09:34AM	Aldeyra Therapeutics Provides Regulatory Update on ADX-2191 (Business Wire) -27.44%
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Alfieri Michael	Principal Financial Officer	Aug 13 '25	Buy	5.30	2,500	13,250	2,500	Aug 15 04:09 PM
Machatha Stephen	Chief Development Officer	Aug 11 '25	Sale	5.15	22,073	113,713	221,799	Aug 13 06:03 PM
Machatha Stephen	Officer	Aug 12 '25	Proposed Sale	5.26	22,074	116,109		Aug 12 05:50 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 03 '25	Sale	1.42	3,400,000	4,828,000	5,875,851	Apr 07 06:43 PM

Open in Screener

SLDB

Solid Biosciences Inc

Nov 14 • 04:00PM ET

4.24

-0.06 -1.40 %

Healthcare • Biotechnology • USA • NASD

SLDB Solid Biosciences Inc daily Stock Chart

Peers: SRPT PFE BMRN BLUE QURE EDIT RGEN NTLA ABEO VYGR

| Held by: VTI IWM VXF IWN VTWO IBB DFAS IWC VFMO AVSC

Index	RUT	P/E	-	EPS (ttm)	-2.49	Insider Own	24.60%	Shs Outstand	77.88M	Perf Week	4.43%
Market Cap	330.34M	Forward P/E	-	EPS next Y	-2.04	Insider Trans	-0.03%	Shs Float	58.74M	Perf Month	-31.17%
Enterprise Value	116.14M	PEG	-	EPS next Q	-0.51	Inst Own	82.03%	Short Float	15.19%	Perf Quarter	-29.68%
Income	-167.13M	P/S	-	EPS this Y	31.21%	Inst Trans	8.93%	Short Ratio	8.23	Perf Half Y	53.07%
Sales	0.00M	P/B	1.52	EPS next Y	2.95%	ROA	-68.82%	Short Interest	8.92M	Perf YTD	6.00%
Book/sh	2.80	P/C	1.40	EPS next 5Y	14.41%	ROE	-86.83%	52W High	7.37 -42.47%	Perf Year	-23.05%
Cash/sh	3.03	P/FCF	-	EPS past 3/5Y	32.97% 41.25%	ROIC	-70.35%	52W Low	2.41 75.93%	Perf 3Y	-33.33%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.53% 8.87%	Perf 5Y	-91.05%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.88%	Oper. Margin	-	ATR (14)	0.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.74	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.88	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	6.74	EPS Q/Q	38.60%	SMA20	-15.81%	Beta	3.01	Target Price	15.17
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	-22.19%	Rel Volume	1.46	Prev Close	4.30
Employees	100	LT Debt/Eq	0.09	Earnings	Nov 03 AMC	SMA200	-11.97%	Avg Volume	1.08M	Price	4.24
IPO	Jan 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-9.34% -	Trades		Volume	1,581,624	Change	-1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-25	Initiated	Citigroup	Buy	$14
Jan-08-25	Initiated	Truist	Buy	$16
Dec-13-24	Initiated	Wedbush	Outperform	$16
Dec-10-24	Initiated	JMP Securities	Mkt Outperform	$15
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight	$10 → $15
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-31-24	Resumed	Piper Sandler	Overweight	$20
Mar-28-24	Initiated	William Blair	Outperform	$40
Mar-15-24	Initiated	Citigroup	Buy	$16
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $20
Dec-08-23	Initiated	H.C. Wainwright	Buy	$9
Jul-12-21	Initiated	Piper Sandler	Neutral	$6
May-27-21	Initiated	Jefferies	Buy	$7
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform	$3 → $15
Mar-09-21	Initiated	Barclays	Overweight	$13
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral	$2 → $7
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform	$22
Aug-29-19	Downgrade	Citigroup	Neutral → Sell	$6

Show Previous Ratings

Nov-11-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +9.16%
Nov-06-25 08:00AM	Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy (GlobeNewswire) +7.25%
Nov-04-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -15.29% -10.78%
Nov-03-25 04:05PM	Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions (GlobeNewswire)
Oct-30-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Oct-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Present at Upcoming Scientific Meetings (GlobeNewswire)
Sep-25-25 08:00AM	Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting (GlobeNewswire) -5.13%
Sep-23-25 08:00AM	Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101 (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Aug-28-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-25 04:07PM	Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +10.60%
03:33PM	Brutal 2025 for Sarepta-Analysts Still Call for 179% Upside (MarketBeat)
Aug-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-23-25 08:00AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +8.51%
08:30AM	Loading…
Jul-21-25 08:30AM	Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors (GlobeNewswire)
Jul-09-25 10:17AM	Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with 'Buy' Rating and $14 PT (Insider Monkey) +5.34%
Jul-08-25 04:05PM	Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (GlobeNewswire) +6.72%
Jul-01-25 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.54% +5.87%
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-18-25 11:39AM	Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (MarketBeat)
Jun-03-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-25 08:00AM	Solid Biosciences to Participate at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.24%
May-15-25 04:06PM	Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.95%
May-01-25 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.27% +18.08%
Apr-30-25 08:00AM	Solid Biosciences to Participate at The Citizens Life Sciences Conference (GlobeNewswire) +8.52%
Apr-29-25 08:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting (GlobeNewswire) -5.57%
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -9.18%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
Apr-07-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) -5.62%
08:00AM	Loading…
Apr-01-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.89%
07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha) -5.12%
Mar-14-25 10:29PM	Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month (Insider Monkey) +5.30%
Mar-12-25 08:00AM	Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (GlobeNewswire)
Mar-07-25 09:55AM	Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade (Zacks)
Mar-06-25 04:16PM	Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-25 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire) +8.47%
Mar-04-25 08:33PM	Is Solid Biosciences Inc. (SLDB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
04:07PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 08:02AM	Solid Biosciences stock soars on early success in DMD gene therapy trial (Clinical Trials Arena) +22.08%
Feb-18-25 07:00AM	Solid Biosciences Announces Pricing of Underwritten Offering (GlobeNewswire) +31.51%
06:45AM	Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003 (GlobeNewswire)
06:36AM	Solid says early data suggest differentiated Duchenne gene therapy (BioPharma Dive)
Feb-09-25 06:12AM	Analysts Predict Up to ~450% Surge for These 2 Strong Buy Penny Stocks (TipRanks)
Feb-04-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-21-25 08:30AM	Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia (GlobeNewswire)
Jan-15-25 04:05PM	Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines (GlobeNewswire)
Jan-08-25 04:05PM	Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.68%
Jan-07-25 04:15PM	Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia (GlobeNewswire)
Jan-06-25 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-23-24 04:05PM	Solid Biosciences Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Dec-13-24 01:52PM	Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst (Benzinga)
Dec-04-24 08:05AM	Solid Biosciences reports inducement grant under Nasdaq listing rule (TipRanks)
08:00AM	Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies (GlobeNewswire)
Dec-03-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.54%
Nov-26-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-24 08:00AM	Solid Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-24 04:05PM	Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.03%
Nov-04-24 08:00AM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-31-24 08:00AM	Solid Biosciences to Participate at the Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-02-24 04:15PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-23-24 08:00AM	Solid Biosciences to Participate at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-12-24 08:00AM	Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-04-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 04:08PM	Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +14.54%
Aug-05-24 08:00AM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 04:19PM	Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.58%
08:00AM	Solid Biosciences Joins the Russell 3000 Index (GlobeNewswire)
Jun-21-24 07:52AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-04-24 04:00PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-15-24 12:53PM	SLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024 (InvestorPlace)
07:52AM	Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results (GlobeNewswire)
May-07-24 07:00AM	Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire)
May-02-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.23%
Apr-03-24 04:05PM	Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 10:35AM	Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug (Zacks)
07:20AM	Solid Biosciences' SGT-003 receives rare pediatric disease designation (Pharmaceutical Business Review)
Apr-01-24 07:45AM	Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire) -6.61%
Mar-28-24 04:08PM	How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback (Investor's Business Daily) -6.53%
Mar-27-24 07:00AM	Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium (GlobeNewswire) +5.01%
Mar-13-24 07:44AM	Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results (GlobeNewswire) +7.28%
Mar-07-24 07:00AM	Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD (GlobeNewswire) +7.86%
Mar-06-24 08:00AM	Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Jan-17-24 11:27AM	Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up (Zacks)
Jan-16-24 01:10PM	Hedge Fund and Insider Trading News: Anthony Scaramucci, Bill Ackman, Rokos Capital Management, ExodusPoint Capital, Alden Global Capital, Solid Biosciences Inc. (SLDB), and More (Insider Monkey)
08:00AM	Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire)
Jan-15-24 10:18AM	Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why (Zacks)
Jan-08-24 07:09AM	Solid Biosciences Announces $109 Million Private Placement (GlobeNewswire) +7.59%
Jan-04-24 08:00AM	Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-23 05:37AM	Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up (Zacks) -12.15%
Dec-07-23 08:00AM	Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003 (GlobeNewswire) +68.42%
Nov-22-23 08:00AM	Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +9.17%
Nov-16-23 08:29AM	Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND (Zacks)
Nov-14-23 04:05PM	Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 (GlobeNewswire) +27.93%
Nov-09-23 08:00AM	Solid Biosciences to Participate at Jefferies London Healthcare Conference (GlobeNewswire) -23.66%
Nov-08-23 04:17PM	Solid Biosciences Provides Third Quarter Business Update and Financial Results (GlobeNewswire)

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ganot Ilan	Director	Nov 10 '25	Sale	4.12	3,278	13,505	95,412	Nov 13 04:05 PM
Brooks Gabriel	Chief Medical Officer	Oct 20 '25	Sale	5.96	2,895	17,254	33,819	Oct 21 04:05 PM
Kahn Clare	Director	Mar 11 '25	Buy	5.34	1,860	9,924	2,960	Mar 13 04:05 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 19 '25	Buy	4.03	1,000,000	4,030,000	5,034,582	Feb 21 05:48 PM
PERCEPTIVE ADVISORS LLC	Director	Feb 19 '25	Buy	4.03	5,000,000	20,150,000	11,833,539	Feb 21 04:17 PM
Adage Capital Management, L.P.	10% Owner	Feb 18 '25	Buy	7.56	252,545	1,909,240	4,248,084	Feb 19 04:16 PM
Hanrahan Jessie	Chief Regulatory Officer	Feb 14 '25	Sale	3.96	3,079	12,193	19,281	Feb 18 04:05 PM
Brooks Gabriel	Chief Medical Officer	Feb 14 '25	Sale	3.96	3,256	12,894	22,812	Feb 18 04:05 PM
Tan Kevin	CFO & Treasurer	Feb 14 '25	Sale	3.96	3,164	12,529	32,250	Feb 18 04:05 PM
Howton David T	Chief Operating Officer	Feb 14 '25	Sale	3.96	5,561	22,022	24,789	Feb 18 04:05 PM
Herzich Paul	Chief Technology Officer	Feb 14 '25	Sale	3.96	2,688	10,644	18,388	Feb 18 04:05 PM
Cumbo Alexander	President and CEO	Feb 14 '25	Sale	3.96	11,365	45,005	60,717	Feb 18 04:05 PM
Ganot Ilan	Director	Feb 14 '25	Sale	3.96	1,711	6,776	14,839	Feb 18 04:05 PM
Howton David T	Officer	Feb 14 '25	Proposed Sale	3.96	5,561	22,022		Feb 14 05:25 PM
Herzich Paul	Officer	Feb 14 '25	Proposed Sale	3.96	2,688	10,644		Feb 14 05:25 PM
Tan Kevin	Officer	Feb 14 '25	Proposed Sale	3.96	3,164	12,529		Feb 14 05:23 PM
Cumbo Alexander	Officer	Feb 14 '25	Proposed Sale	3.96	11,365	45,005		Feb 14 05:23 PM
Hanrahan Jessie	Officer	Feb 14 '25	Proposed Sale	3.96	3,079	12,193		Feb 14 05:20 PM
Ganot Ilan	Director	Jan 28 '25	Sale	3.11	144	448	11,689	Jan 29 06:14 PM
Tan Kevin	CFO & Treasurer	Jan 10 '25	Sale	3.89	4,073	15,849	24,789	Jan 13 06:51 PM
Ganot Ilan	Director	Jan 06 '25	Sale	4.31	1,056	4,551	11,445	Jan 07 05:29 PM
Hanrahan Jessie	Chief Regulatory Officer	Dec 03 '24	Sale	5.60	4,610	25,822	14,235	Dec 04 05:34 PM
Howton David T	Officer	Dec 03 '24	Proposed Sale	5.60	5,072	28,396		Dec 04 05:33 PM
Cumbo Alexander	President and CEO	Dec 03 '24	Sale	5.60	11,114	62,236	38,484	Dec 04 05:27 PM
Howton David T	Chief Operating Officer	Dec 03 '24	Sale	5.60	5,072	28,396	15,663	Dec 04 05:04 PM
Herzich Paul	Chief Technology Officer	Dec 03 '24	Sale	5.60	2,777	15,551	12,182	Dec 04 04:42 PM
Cumbo Alexander	Officer	Dec 03 '24	Proposed Sale	5.79	10,687	61,878		Dec 03 05:35 PM

Open in Screener

MGTX

MeiraGTx Holdings plc

Nov 14 • 04:00PM ET

8.19

-0.07 -0.85 %

Healthcare • Biotechnology • USA • NASD

MGTX MeiraGTx Holdings plc daily Stock Chart

Peers: SRPT BLUE AGIO EPIX CLLS BNTX ADVM ALLO EDIT CRSP

| Held by: IWM IBB IWO VTWO VHT IWC IWN VFMO PRFZ VTWG

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	27.60%	Shs Outstand	80.48M	Perf Week	-3.31%
Market Cap	659.22M	Forward P/E	-	EPS next Y	-0.84	Insider Trans	-0.64%	Shs Float	58.28M	Perf Month	0.74%
Enterprise Value	732.44M	PEG	-	EPS next Q	-0.57	Inst Own	56.46%	Short Float	6.53%	Perf Quarter	2.76%
Income	-168.69M	P/S	24.04	EPS this Y	24.33%	Inst Trans	7.23%	Short Ratio	9.27	Perf Half Y	64.13%
Sales	27.42M	P/B	-	EPS next Y	47.43%	ROA	-69.00%	Short Interest	3.81M	Perf YTD	34.48%
Book/sh	-0.50	P/C	44.42	EPS next 5Y	27.24%	ROE	-611.42%	52W High	9.73 -15.83%	Perf Year	22.97%
Cash/sh	0.18	P/FCF	-	EPS past 3/5Y	-5.50% -5.10%	ROIC	-	52W Low	4.55 80.00%	Perf 3Y	22.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-4.07% 20.15%	Gross Margin	-4.57%	Volatility	11.40% 8.52%	Perf 5Y	-42.81%
Dividend TTM	-	EV/Sales	26.71	EPS Y/Y TTM	-61.92%	Oper. Margin	-597.91%	ATR (14)	0.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.22	Sales Y/Y TTM	96.83%	Profit Margin	-615.27%	RSI (14)	44.85	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.22	EPS Q/Q	-13.66%	SMA20	-5.80%	Beta	1.40	Target Price	28.57
Payout	-	Debt/Eq	-	Sales Q/Q	-96.24%	SMA50	-0.93%	Rel Volume	1.19	Prev Close	8.26
Employees	381	LT Debt/Eq	-	Earnings	Nov 13 BMO	SMA200	13.89%	Avg Volume	410.79K	Price	8.19
IPO	Jun 08, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.53% -94.11%	Trades		Volume	487,415	Change	-0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Raymond James	Strong Buy	$29
Jul-31-24	Resumed	Chardan Capital Markets	Buy	$36
Oct-23-20	Initiated	RBC Capital Mkts	Outperform	$27
Sep-15-20	Resumed	BofA Securities	Buy	$20
Sep-03-19	Initiated	Piper Jaffray	Overweight	$40
Feb-27-19	Reiterated	Chardan Capital Markets	Buy	$30 → $40
Jul-03-18	Initiated	BofA/Merrill	Buy
Jul-03-18	Initiated	Barclays	Overweight

Nov-13-25 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Third Quarter 2025 Financial and Operational Results (GlobeNewswire)
Nov-10-25 09:15AM	Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology (GlobeNewswire)
Nov-06-25 06:25PM	Alector (ALEC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:35PM	Loading…
Nov-05-25 05:35PM	Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
10:00AM	MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-22-25 08:18AM	MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last? (Zacks) -5.62%
Oct-07-25 08:00AM	MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress (GlobeNewswire)
Aug-14-25 09:10AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:35AM	Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Second Quarter 2025 Financial and Operational Results (GlobeNewswire)
Aug-07-25 08:45AM	InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jun-27-25 08:03AM	3 Promising Genomics Stocks to Keep an Eye On in 2025 (Zacks)
May-13-25 04:30PM	MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting (GlobeNewswire) -8.36% -10.00%
09:15AM	Loading…
09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports First Quarter 2025 Financial and Operational Results (GlobeNewswire)
May-09-25 08:00AM	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease (GlobeNewswire)
Apr-10-25 09:49AM	Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? (Zacks) -5.59%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -9.14%
Mar-25-25 10:50AM	MeiraGTx Holdings: Gaining Regulatory Focus (SeekingAlpha)
09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-18-25 03:29AM	MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinsons Treatment (Insider Monkey)
Mar-14-25 08:27AM	MeiraGTx and Hologen launch AI-backed gene therapy venture (Pharmaceutical Technology) -5.58%
Mar-13-25 08:05AM	MeiraGTx spins Parkinsons, obesity gene therapies into AI startup (BioPharma Dive) +28.71%
08:00AM	MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
07:30AM	MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process (GlobeNewswire)
Feb-24-25 07:30AM	MeiraGTx seeks UK approval after gene therapy restores sight in children born blind (Pharmaceutical Technology)
Feb-21-25 06:30AM	MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy (GlobeNewswire) +6.88%
Jan-22-25 08:30AM	MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations (GlobeNewswire) -5.77%
03:25PM	Loading…
Jan-20-25 03:25PM	Is MeiraGTx Holdings plc (MGTX) Among Billionaire Joseph Edelman's Long-Term Stock Picks? (Insider Monkey)
Dec-29-24 06:19AM	MeiraGTx Holdings plc (MGTX): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-10-24 09:38AM	MeiraGTx granted RMAT designation by U.S. FDA to AAV2-hAQP1 (TipRanks)
Dec-09-24 08:00AM	MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire) +5.54%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-13-24 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.71%
08:00AM	MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
Oct-22-24 08:00AM	MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress (GlobeNewswire)
Oct-16-24 04:43PM	MeiraGTxs Parkinsons gene therapy shows promise in Phase I/II study (Clinical Trials Arena) +11.07%
07:30AM	MeiraGTx Holdings Reports Promising Parkinsons Therapy Results (TipRanks)
06:45AM	MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains? (Zacks)
Oct-15-24 12:13PM	Small Cap-MeiraGTx Reveals Encouraging Data From Parkinson's Study Showing Significant, Clinically Meaningful Changes in Key Efficacy Endpoints (Benzinga) +14.87%
07:00AM	MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease (GlobeNewswire)
Oct-09-24 04:30PM	MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference (GlobeNewswire)
Aug-30-24 09:46AM	Is MeiraGTx Holdings plc (MGTX) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-12-24 07:40AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.47%
07:05AM	MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results (GlobeNewswire)
07:03AM	MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi (GlobeNewswire)
May-24-24 09:57AM	Ireland the jewel in the life sciences crown? (Medical Device Network)
May-22-24 09:32AM	Jim Cramer is Recommending These Stocks (Insider Monkey)
May-10-24 03:09PM	MeiraGTx Holdings PLC Reports First Quarter 2024 Financial Results (GuruFocus.com)
May-09-24 01:53PM	MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00AM	MeiraGTx Reports First Quarter 2024 Financial and Operational Results (GlobeNewswire)
Apr-24-24 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-18-24 04:30PM	MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference (GlobeNewswire)
Mar-14-24 10:31AM	MeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023 (GuruFocus.com) -7.09%
09:45AM	MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
08:30AM	MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates (GlobeNewswire)
Feb-13-24 08:00AM	MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals (GlobeNewswire) -9.55%
Feb-01-24 07:30AM	Graviton Bioscience Announces Strategic Investment from Sanofi to Advance Development of the Next Generation of Selective ROCK2 Inhibitors (PR Newswire)
Jan-10-24 09:55AM	Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet (Zacks)
08:49AM	MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Jan-02-24 12:17PM	MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why (Zacks)
Dec-25-23 09:55AM	Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade (Zacks)
Dec-21-23 07:07AM	J&J bets bigger on MeiraGTxs eye gene therapy (BioPharma Dive) +32.59%
07:00AM	MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million (GlobeNewswire)
Nov-21-23 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-14-23 07:21PM	MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress (GuruFocus.com)
08:00AM	MeiraGTx Announces Third Quarter 2023 Financial and Operational Results (GlobeNewswire)
Oct-31-23 08:00AM	BestGrowthStocks.Com: MeiraGTx Holdings plc Actively Pursuing Strategic Partnerships and Asset Interest, Potential Transactions (News Direct)
Oct-30-23 08:25AM	Sanofi invests in MeiraGTx and its gene-regulating technology (BioPharma Dive) +20.27%
07:30AM	MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities (GlobeNewswire)
Oct-24-23 08:30AM	MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress (GlobeNewswire)
Aug-10-23 09:15AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	MeiraGTx Reports Second Quarter 2023 Financial and Operational Results (GlobeNewswire)
Aug-01-23 09:10AM	MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology (GlobeNewswire)
Jul-19-23 08:30AM	MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing (GlobeNewswire) +8.04%
Jun-28-23 07:53PM	MeiraGTx Holdings PLC (MGTX) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks) +8.20%
Jun-27-23 03:41PM	MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness (Benzinga) -7.31%
07:30AM	MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire)
Jun-22-23 04:01PM	MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Companys Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023 (GlobeNewswire)
Jun-16-23 10:00AM	MeiraGTx Holdings (NASDAQ:MGTX) shareholders have endured a 43% loss from investing in the stock three years ago (Simply Wall St.)
Jun-02-23 09:55AM	Does MeiraGTx Holdings PLC (MGTX) Have the Potential to Rally 320.9% as Wall Street Analysts Expect? (Zacks) +9.29%
May-17-23 09:55AM	Wall Street Analysts Predict a 314.29% Upside in MeiraGTx Holdings PLC (MGTX): Here's What You Should Know (Zacks) +10.00%
May-16-23 09:00AM	MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting (GlobeNewswire) +13.82%
May-11-23 08:00AM	MeiraGTx Reports First Quarter 2023 Financial and Operational Results (GlobeNewswire) -5.97%
May-03-23 08:30AM	MeiraGTx Announces $60 Million Private Placement of Ordinary Shares (GlobeNewswire) +12.52%
Apr-21-23 08:30AM	MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting (GlobeNewswire)
Apr-20-23 05:00PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-12-23 11:41AM	MeiraGTx Holdings plc (NASDAQ:MGTX) has caught the attention of institutional investors who hold a sizeable 31% stake (Simply Wall St.)
Mar-16-23 06:06AM	A Look At The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX) (Simply Wall St.)
Mar-14-23 08:00AM	MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results (GlobeNewswire)
Feb-13-23 03:00AM	JNJ Bought Up Biotech Stock MeiraGTx. It Sold Procept BioRobotics. (Barrons.com) +7.74%
Dec-13-22 01:56PM	MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms (Benzinga)
07:30AM	MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia (GlobeNewswire)
06:26AM	MeiraGTx Holdings (NASDAQ:MGTX) investors are sitting on a loss of 71% if they invested three years ago (Simply Wall St.)
Dec-08-22 04:30PM	MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022 (GlobeNewswire)
Nov-22-22 04:30PM	MeiraGTx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-16-22 06:02AM	MeiraGTx Holdings Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-11-22 10:02AM	Time To Worry? Analysts Are Downgrading Their MeiraGTx Holdings plc (NASDAQ:MGTX) Outlook (Simply Wall St.)

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on the development and manufacturing of genetic medicines to treat both inherited and more common conditions with severe unmet need. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Giroux Richard	CFO & COO	Oct 21 '25	Sale	8.87	24,000	212,880	829,494	Oct 21 09:19 PM
Richard Giroux	Officer	Oct 21 '25	Proposed Sale	8.87	24,000	212,880		Oct 21 09:17 PM
Forbes Alexandria	PRESIDENT & CEO	Oct 07 '25	Sale	8.39	47,500	398,525	1,313,983	Oct 07 09:49 PM
Alexandria Forbes	Officer	Oct 07 '25	Proposed Sale	8.39	47,500	398,525		Oct 07 09:47 PM
Giroux Richard	CFO & COO	Jul 22 '25	Sale	8.52	24,000	204,480	853,494	Jul 22 09:01 PM
Richard Giroux	Officer	Jul 22 '25	Proposed Sale	8.52	24,000	204,480		Jul 22 08:58 PM
Forbes Alexandria	PRESIDENT & CEO	Jul 08 '25	Sale	7.97	47,500	378,575	1,361,483	Jul 08 08:57 PM
Alexandria Forbes	Officer	Jul 08 '25	Proposed Sale	7.97	47,500	378,575		Jul 08 08:55 PM
Giroux Richard	CFO & COO	Apr 22 '25	Sale	6.00	24,000	144,000	882,494	Apr 22 08:54 PM
Richard Giroux	Officer	Apr 22 '25	Proposed Sale	6.00	24,000	144,000		Apr 22 08:52 PM
Forbes Alexandria	PRESIDENT & CEO	Apr 08 '25	Sale	5.34	47,500	253,650	1,408,983	Apr 08 09:05 PM
Forbes Alexandria	President / CEO	Apr 08 '25	Proposed Sale	5.29	47,500	251,265		Apr 08 04:55 PM
Giroux Richard	CFO & COO	Jan 21 '25	Sale	6.29	24,000	150,960	849,947	Jan 21 09:17 PM
Giroux Richard	Officer	Jan 21 '25	Proposed Sale	6.41	24,000	153,840		Jan 21 08:58 PM
Forbes Alexandria	PRESIDENT & CEO	Jan 07 '25	Sale	6.47	35,839	231,878	1,395,102	Jan 10 09:07 PM
Forbes Alexandria	PRESIDENT & CEO	Jan 08 '25	Sale	6.30	11,661	73,464	1,383,441	Jan 10 09:07 PM
Forbes Alexandria	President / CEO	Jan 07 '25	Proposed Sale	6.34	47,500	301,150		Jan 07 09:15 PM

Open in Screener

ATXS

Astria Therapeutics Inc

Nov 14 • 04:00PM ET

12.57

+0.13 1.05 %

Healthcare • Biotechnology • USA • NASD

ATXS Astria Therapeutics Inc daily Stock Chart

Peers: REGN VRTX PFE GILD AMGN BIIB SRPT ALNY NBIX BLUE

| Held by: IWM VTI IWN IBB VXF SCHA VTWO ARB IWC AVSC

Index	RUT	P/E	-	EPS (ttm)	-2.15	Insider Own	24.85%	Shs Outstand	56.43M	Perf Week	0.48%
Market Cap	717.56M	Forward P/E	-	EPS next Y	-2.23	Insider Trans	0.00%	Shs Float	42.90M	Perf Month	3.97%
Enterprise Value	589.62M	PEG	-	EPS next Q	-0.55	Inst Own	77.57%	Short Float	7.33%	Perf Quarter	85.40%
Income	-124.03M	P/S	1010.65	EPS this Y	-25.67%	Inst Trans	-15.12%	Short Ratio	1.92	Perf Half Y	217.42%
Sales	0.71M	P/B	5.14	EPS next Y	-5.56%	ROA	-39.16%	Short Interest	3.14M	Perf YTD	40.60%
Book/sh	2.44	P/C	3.15	EPS next 5Y	-2.36%	ROE	-43.15%	52W High	12.72 -1.14%	Perf Year	12.63%
Cash/sh	3.99	P/FCF	-	EPS past 3/5Y	59.12% 34.65%	ROIC	-52.49%	52W Low	3.56 253.59%	Perf 3Y	66.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	0.00%	Volatility	1.77% 1.82%	Perf 5Y	54.04%
Dividend TTM	-	EV/Sales	830.45	EPS Y/Y TTM	-2.74%	Oper. Margin	-19335.69%	ATR (14)	0.33	Perf 10Y	-97.21%
Dividend Ex-Date	-	Quick Ratio	10.78	Sales Y/Y TTM	-	Profit Margin	-17567.99%	RSI (14)	69.97	Recom	2.75
Dividend Gr. 3/5Y	- -	Current Ratio	10.78	EPS Q/Q	-28.56%	SMA20	0.98%	Beta	0.09	Target Price	23.83
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	27.30%	Rel Volume	0.52	Prev Close	12.44
Employees	78	LT Debt/Eq	0.01	Earnings	Nov 12 BMO	SMA200	83.12%	Avg Volume	1.64M	Price	12.57
IPO	Jun 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-40.77% -93.38%	Trades		Volume	859,148	Change	1.05%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-17-25	Reiterated	H.C. Wainwright	Buy	$16 → $20
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$47
Jan-31-25	Initiated	JMP Securities	Mkt Outperform	$26
Jul-29-24	Initiated	TD Cowen	Buy	$35
Mar-28-23	Initiated	Evercore ISI	Outperform	$18

Nov-12-25 01:55PM	Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
09:10AM	Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire)
Nov-06-25 08:00AM	Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart (Business Wire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
08:00AM	Loading…
08:00AM	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (Business Wire)
Oct-15-25 10:05AM	Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX (Zacks)
05:16AM	BioCryst to buy Astria Therapeutics for $700m in enterprise value (Pharmaceutical Technology)
Oct-14-25 07:32AM	BioCryst goes all in on rare swelling disease with Astria deal (BioPharma Dive) +37.07%
07:00AM	BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile (Business Wire)
Oct-11-25 12:00PM	3 Biotech Stocks That Could More Than Triple if Their Trials Succeed (Barchart)
Oct-09-25 08:00AM	Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting (Business Wire)
Oct-08-25 08:00AM	Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema (Business Wire) +12.45%
Oct-03-25 08:00AM	Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA (Business Wire)
Oct-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Loading…
08:00AM	Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial (Business Wire)
Sep-17-25 08:00AM	Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology (Business Wire)
Sep-11-25 12:00PM	All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy (Zacks)
Sep-09-25 09:55AM	Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade (Zacks)
Sep-08-25 05:03PM	Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Sep-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.07%
08:00AM	Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025 (Business Wire)
Sep-02-25 07:30AM	2 Strong Buy Growth Stocks Offering 300% or Higher Upside (Barchart) +6.63%
Aug-27-25 08:00AM	Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference (Business Wire)
Aug-15-25 09:55AM	Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect? (Zacks)
Aug-12-25 04:10PM	Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire)
Aug-07-25 05:55AM	Astria Therapeutics licenses navenibart rights to Kaken for HAE (Pharmaceutical Technology)
Aug-06-25 08:00AM	Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan (Business Wire)
Aug-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.03%
Jul-31-25 11:40PM	Astria Therapeutics Announces Positive Initial Results from Long-Term Navenibart Trial in HAE Patients (Insider Monkey) -5.20%
08:00AM	Loading…
Jul-07-25 08:00AM	Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit (Business Wire) +6.71%
Jul-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.52%
Jun-18-25 08:00AM	Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit (Business Wire)
Jun-13-25 07:00AM	Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress (Business Wire)
Jun-06-25 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress (Business Wire) +14.75%
Jun-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.45%
May-28-25 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference (Business Wire) +6.85%
May-23-25 08:00AM	Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop (Business Wire)
May-22-25 08:00AM	Astria Therapeutics to Present at Upcoming Eastern Allergy Conference (Business Wire)
May-13-25 04:10PM	Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire) -10.76%
May-09-25 08:30AM	Is Astria Therapeutics, Inc. (ATXS) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-01-25 08:00AM	Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology (Business Wire)
Apr-30-25 08:00AM	Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-02-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.70%
Mar-11-25 08:00AM	Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update (Business Wire) +11.17%
Mar-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 08:00AM	Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema (Business Wire)
Feb-25-25 08:00AM	Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-20-25 08:00AM	Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress (Business Wire)
Feb-04-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Feb-03-25 08:00AM	Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session (Business Wire) -5.47%
Jan-23-25 08:00AM	Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis (Business Wire)
Jan-13-25 08:00AM	Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE (Business Wire)
Jan-03-25 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-11-24 08:00AM	Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE (Business Wire)
Dec-10-24 08:00AM	Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis (Business Wire)
Dec-03-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 04:10PM	Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire)
08:00AM	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference (Business Wire)
Nov-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting (Business Wire)
Oct-21-24 08:00AM	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (Business Wire)
Oct-17-24 08:16AM	Astria Therapeutics' navenibart gains orphan medicinal status from EC (Pharmaceutical Business Review)
Oct-16-24 08:00AM	European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics Investigational Therapy for the Treatment of Hereditary Angioedema (Business Wire)
Oct-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 08:00AM	Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema (Business Wire)
Sep-27-24 08:00AM	Astria Therapeutics to Present at Upcoming Global Angioedema Forum (Business Wire)
Sep-19-24 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress (Business Wire) +6.37%
Sep-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Bradykinin Symposium (Business Wire)
Aug-29-24 08:00AM	Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-12-24 04:10PM	Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire) +7.48%
04:00PM	Astria Therapeutics Chooses Ypsomed's YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema (Business Wire)
Aug-07-24 08:00AM	Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference (Business Wire)
Aug-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.61% -5.36%
Jul-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference (Business Wire)
May-24-24 08:00AM	Astria Therapeutics to Present at Upcoming Eastern Allergy Conference (Business Wire)
May-23-24 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress (Business Wire)
May-09-24 04:10PM	Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire) +6.27%
May-08-24 08:00AM	Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting (Business Wire)
May-02-24 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-09-24 08:00AM	Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors (Business Wire)
Apr-03-24 07:00PM	Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS) (GuruFocus.com) -5.47%
04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-25-24 07:30AM	Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE (Business Wire)
Mar-05-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.14%
Mar-04-24 10:52PM	ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-20-24 08:00AM	Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-06-24 08:00AM	Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +6.25%
Feb-05-24 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.95%
Jan-30-24 07:29PM	Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (GuruFocus.com) +6.62%
09:08AM	Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering (Business Wire)
Dec-04-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-23 08:00AM	Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress (Business Wire)

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Open in Screener

VRCA

Verrica Pharmaceuticals Inc

Nov 14 • 04:00PM ET

3.93

+0.06 1.55 %

Healthcare • Biotechnology • USA • NASD

VRCA Verrica Pharmaceuticals Inc daily Stock Chart

Peers: DERM HRTX ACRS SUPN CLSD KPTI XERS ADMA DMAC EYPT

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-3.44	Insider Own	59.64%	Shs Outstand	9.49M	Perf Week	13.58%
Market Cap	37.12M	Forward P/E	-	EPS next Y	-1.63	Insider Trans	0.00%	Shs Float	3.81M	Perf Month	-7.09%
Enterprise Value	51.76M	PEG	-	EPS next Q	-0.51	Inst Own	32.22%	Short Float	11.02%	Perf Quarter	-36.15%
Income	-26.01M	P/S	1.20	EPS this Y	94.20%	Inst Trans	6.17%	Short Ratio	1.49	Perf Half Y	-40.66%
Sales	30.83M	P/B	-	EPS next Y	-90.13%	ROA	-70.48%	Short Interest	0.42M	Perf YTD	-43.86%
Book/sh	-1.80	P/C	1.76	EPS next 5Y	66.40%	ROE	-1546.58%	52W High	13.60 -71.10%	Perf Year	-57.28%
Cash/sh	2.23	P/FCF	-	EPS past 3/5Y	-4.45% -5.46%	ROIC	-469.74%	52W Low	3.28 19.82%	Perf 3Y	-81.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-14.25% -	Gross Margin	91.36%	Volatility	8.63% 7.50%	Perf 5Y	-94.99%
Dividend TTM	-	EV/Sales	1.68	EPS Y/Y TTM	55.79%	Oper. Margin	-51.14%	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.11	Sales Y/Y TTM	234.73%	Profit Margin	-84.38%	RSI (14)	50.93	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	1.19	EPS Q/Q	99.41%	SMA20	5.02%	Beta	1.61	Target Price	16.33
Payout	-	Debt/Eq	-	Sales Q/Q	905.39%	SMA50	-5.60%	Rel Volume	0.14	Prev Close	3.87
Employees	71	LT Debt/Eq	-	Earnings	Nov 14 AMC	SMA200	-28.98%	Avg Volume	281.46K	Price	3.93
IPO	Jun 15, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	92.06% -63.02%	Trades		Volume	40,341	Change	1.55%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

Nov-14-25 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-10-25 08:00AM	Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +11.85%
Oct-24-25 11:00AM	Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 04:05PM	Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union (GlobeNewswire) +7.95% -9.82%
Oct-07-25 04:05PM	Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Sep-19-25 08:00AM	Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH (TO-208) in Japan for the Treatment of Molluscum Contagiosum (GlobeNewswire) +8.66%
Sep-02-25 07:00AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 03:12AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Aug-12-25 05:20PM	Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-11-25 09:42AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.51%
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.20%
07:00AM	Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 (GlobeNewswire)
Jul-09-25 07:00AM	Verrica Pharmaceuticals Reports Strong Growth in YCANTH Dispensed Applicator Units in 2Q 2025 (GlobeNewswire)
Jul-01-25 07:00AM	Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire) +13.37%
08:00AM	Loading…
May-28-25 08:00AM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire) -5.78%
May-14-25 08:10AM	Q1 2025 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ... (GuruFocus.com)
May-13-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.63%
04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +15.07%
09:52AM	Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result (GuruFocus.com)
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.97%
May-07-25 08:00AM	Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 (GlobeNewswire) -9.20%
May-02-25 07:10AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates (Zacks)
Apr-30-25 08:00AM	Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York (GlobeNewswire)
Apr-07-25 08:00AM	Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH Dispensed Applicator Units in First Quarter 2025 (GlobeNewswire) +21.75%
Apr-02-25 04:05PM	Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors (GlobeNewswire)
Apr-01-25 09:55AM	Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-31-25 08:00AM	Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
07:00AM	Loading…
Mar-26-25 07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.75%
Mar-12-25 01:48PM	Q4 2024 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.56%
03:08AM	Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com)
Mar-11-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 07:00AM	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 (GlobeNewswire)
Feb-27-25 10:00AM	Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -16.89%
Feb-25-25 04:05PM	Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston (GlobeNewswire)
Jan-21-25 07:00AM	Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference (GlobeNewswire) +5.12%
Dec-20-24 07:00AM	Verrica Provides Business and Operational Update (GlobeNewswire)
Dec-09-24 04:15PM	Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.94% -7.84%
Dec-06-24 08:00AM	Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-21-24 07:30AM	Verrica Announces Pricing of $42.0 Million Public Offering (GlobeNewswire) +11.56%
Nov-20-24 04:05PM	Verrica Announces Proposed Public Offering (GlobeNewswire)
Nov-04-24 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition (GlobeNewswire) -6.54% -44.23%
Oct-24-24 07:00AM	Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-09-24 06:21PM	Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)
Oct-02-24 07:30AM	Verrica Pharmaceuticals Announces Restructuring of Commercial Organization (GlobeNewswire) -18.98%
Sep-29-24 08:02AM	Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:27AM	Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers? (Insider Monkey) -5.68%
Sep-20-24 05:21AM	Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) (Newsfile) -6.70%
Sep-04-24 07:30AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York (GlobeNewswire) +5.50%
Aug-15-24 07:32AM	Verrica stock drops after half patients tumours gone in skin cancer trial (Clinical Trials Arena) -6.73%
Aug-14-24 09:52AM	Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -40.80%
08:55AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma (GlobeNewswire)
Aug-06-24 07:30AM	Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 (GlobeNewswire) -5.45%
Jul-15-24 11:57AM	7 Short-Squeeze Stocks That Could Beat Down the Bears (InvestorPlace)
Jul-01-24 07:30AM	Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. (GlobeNewswire) +9.05%
May-30-24 04:30PM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-15-24 09:11AM	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth (MT Newswires)
07:30AM	Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire)
May-14-24 09:28AM	HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating (MT Newswires)
08:50AM	Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating (MT Newswires)
03:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +19.50%
09:12AM	Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review (GuruFocus.com)
08:40AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Verrica Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-08-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
May-06-24 06:35AM	Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? (Zacks)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-02-24 07:30AM	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:30AM	Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA (GlobeNewswire) +5.14%
Mar-01-24 09:10AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.31%
Feb-29-24 08:11AM	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com) -7.87%
07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:30AM	Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire) +5.00%
Feb-22-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 07:30AM	Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition (GlobeNewswire) -7.58%
Jan-29-24 07:30AM	Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services (GlobeNewswire)
Jan-22-24 07:44PM	7 Potential Short-Squeeze Stocks Poised for Rapid Gains (InvestorPlace)
Jan-05-24 07:30AM	Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Jan-04-24 07:30AM	Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH for the Treatment of Common Warts (GlobeNewswire)
Jan-03-24 07:30AM	Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH (GlobeNewswire)
Dec-15-23 01:49PM	Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today? (InvestorPlace) +61.97%
06:00AM	Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-11-23 10:13AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 08:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-09-23 07:30AM	Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire) -9.83%
Oct-25-23 07:00AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 (GlobeNewswire)
Sep-27-23 08:00AM	Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023 (GlobeNewswire)
Aug-31-23 08:00AM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 08:30AM	Verrica Pharmaceuticals Announces First Sale of YCANTH to FFF Enterprises (GlobeNewswire)
Aug-23-23 07:30AM	Verrica Issues Statement in Support of FDAs Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum (GlobeNewswire)
Aug-10-23 04:05PM	Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Aug-08-23 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 07:30AM	Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Associations (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hayes Christopher G.	CHIEF LEGAL OFFICER	Mar 17 '25	Sale	0.65	4,315	2,805	176,458	Mar 18 06:45 PM

Open in Screener

ATHA

Athira Pharma Inc

Nov 14 • 04:00PM ET

4.52

-0.18 -3.73 %

Healthcare • Biotechnology • USA • NASD

ATHA Athira Pharma Inc daily Stock Chart

Peers: BIIB SAVA AVXL SAGE QURE PRTA INVA AUPH NBIX ANVS

| Held by: SURI VTI VXF DCOR

Index	-	P/E	-	EPS (ttm)	-9.66	Insider Own	7.68%	Shs Outstand	3.94M	Perf Week	17.40%
Market Cap	17.83M	Forward P/E	-	EPS next Y	-5.10	Insider Trans	-15.58%	Shs Float	3.64M	Perf Month	23.50%
Enterprise Value	-6.49M	PEG	-	EPS next Q	-0.84	Inst Own	43.72%	Short Float	1.82%	Perf Quarter	15.04%
Income	-37.72M	P/S	-	EPS this Y	76.41%	Inst Trans	0.66%	Short Ratio	2.20	Perf Half Y	66.18%
Sales	0.00M	P/B	0.67	EPS next Y	14.21%	ROA	-64.88%	Short Interest	0.07M	Perf YTD	-22.96%
Book/sh	6.79	P/C	0.71	EPS next 5Y	76.92%	ROE	-89.42%	52W High	7.47 -39.51%	Perf Year	-43.50%
Cash/sh	6.40	P/FCF	-	EPS past 3/5Y	-19.25% -73.94%	ROIC	-138.45%	52W Low	2.20 105.88%	Perf 3Y	-83.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.62% 7.18%	Perf 5Y	-97.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	66.10%	Oper. Margin	-	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	58.65	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.70	EPS Q/Q	77.53%	SMA20	7.20%	Beta	2.91	Target Price	4.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	12.23%	Rel Volume	0.18	Prev Close	4.70
Employees	26	LT Debt/Eq	0.02	Earnings	Nov 06 AMC	SMA200	25.00%	Avg Volume	30.10K	Price	4.52
IPO	Sep 18, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	-58.49% -	Trades		Volume	5,381	Change	-3.73%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral	$5 → $0.50
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy	$22
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$20
Jul-07-22	Initiated	Mizuho	Buy	$6
Jun-23-22	Downgrade	Stifel	Buy → Hold	$36 → $5
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold	$32 → $3
May-10-22	Initiated	BTIG Research	Buy	$33
Apr-21-22	Initiated	Berenberg	Buy	$33
Dec-15-21	Initiated	Goldman	Neutral	$16
Oct-13-20	Initiated	Stifel	Buy	$36
Oct-13-20	Initiated	JMP Securities	Mkt Outperform	$51
Oct-13-20	Initiated	Jefferies	Buy	$30
Oct-13-20	Initiated	Goldman	Buy	$53

Show Previous Ratings

Nov-06-25 04:05PM	Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Sep-11-25 09:00AM	Athira Pharma Announces Reverse Stock Split (GlobeNewswire)
Aug-14-25 07:00AM	Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 (GlobeNewswire)
Aug-07-25 04:05PM	Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +5.95%
May-14-25 11:10AM	Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 (TipRanks) -7.25%
11:00AM	Loading…
May-13-25 11:00AM	Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit (GlobeNewswire)
May-09-25 04:05PM	Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.17%
Feb-27-25 04:05PM	Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Dec-06-24 05:30PM	Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND (GlobeNewswire)
Nov-08-24 04:50AM	Athira exploring strategic alternatives after Alzheimers failure (BioPharma Dive) -12.01%
Nov-07-24 04:05PM	Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire) +7.14%
Oct-22-24 07:00AM	Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting (GlobeNewswire) +15.73%
Sep-17-24 09:00AM	Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Sep-04-24 11:40AM	Alzheimers Trial Failure Sends Athira Stock Down 75% (Barrons.com) -78.43%
11:33AM	Athiras stock topples after Alzheimers drug flops in Phase II/III trial (Pharmaceutical Technology)
08:48AM	Loading…
08:48AM	Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks (Benzinga)
Sep-03-24 04:01PM	Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) -8.41%
Aug-23-24 09:40AM	Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? (Zacks) +6.75%
Aug-07-24 09:40AM	Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-01-24 04:05PM	Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Jul-31-24 08:05AM	Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024 (GlobeNewswire)
Jul-10-24 08:51AM	Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up (Zacks)
Jul-09-24 07:00AM	Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) +29.39%
Jun-12-24 07:00AM	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients (GlobeNewswire)
Jun-11-24 07:00AM	Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
May-29-24 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-17-24 05:00PM	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action (GlobeNewswire) -7.01%
May-15-24 10:54PM	ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 (InvestorPlace) +22.62%
04:05PM	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +10.66%
07:00AM	Loading…
May-02-24 07:00AM	Athira Pharma to Participate in Upcoming May Conferences (GlobeNewswire)
Apr-15-24 07:00AM	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer (GlobeNewswire) -15.57%
Apr-11-24 07:00AM	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease (GlobeNewswire) +6.85%
Apr-03-24 07:00AM	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 07:00AM	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference (GlobeNewswire) -13.73%
Feb-28-24 12:00PM	Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-22-24 04:05PM	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.22%
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +12.27%
Feb-08-24 04:02PM	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Jan-08-24 07:00AM	Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update (GlobeNewswire) +10.45%
Jan-03-24 07:00AM	Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Dec-12-23 07:00AM	Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies (GlobeNewswire)
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
Nov-29-23 07:00AM	Athira Pharma to Participate in Sidoti December Small Cap Investor Conference (GlobeNewswire)
Nov-28-23 07:00AM	Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34 International Symposium on ALS/MND (GlobeNewswire) -5.88%
Nov-15-23 08:15AM	Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid- -Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease (GlobeNewswire)
Nov-09-23 04:05PM	Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) -7.33% +6.47%
Nov-08-23 07:00AM	Athira Pharma to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-05-23 04:30PM	Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Sep-28-23 07:00AM	Athira Pharma to Participate in Upcoming October Conferences (GlobeNewswire) +5.26%
Sep-19-23 07:00AM	Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-08-23 12:00PM	All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy (Zacks)
Aug-31-23 09:35AM	Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA) (Zacks)
Aug-29-23 09:55AM	Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-10-23 04:05PM	Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +5.21% -7.26%
Jul-17-23 07:00AM	Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimers Disease (GlobeNewswire)
Jul-06-23 11:52AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Athira Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
Jun-08-23 06:08AM	Andrew Gengos Spends US$192k On Athira Pharma Stock \ (Simply Wall St.)
Jun-07-23 08:10AM	Daily Vickers Top Buyers & Sellers for 06/07/2023 (Argus Research) +12.54%
May-31-23 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-22-23 07:00AM	Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
May-12-23 11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 04:05PM	Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 07:00AM	Athira Pharma to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-23 08:45AM	Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Apr-25-23 04:01PM	Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-11-23 07:00AM	Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-02-23 08:14AM	Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares (Simply Wall St.)
Mar-28-23 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
01:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimers and Parkinsons Diseases at AD/PD 2023 International Conference (GlobeNewswire)
Mar-23-23 04:05PM	Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
Mar-08-23 07:00AM	Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences (GlobeNewswire)
Mar-06-23 07:00AM	Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire)
Feb-01-23 07:00AM	Athira Pharma Announces Publication in Journal of Alzheimers Disease Highlighting Need for Novel Alzheimers Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway (GlobeNewswire)
Jan-31-23 07:00AM	Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer (GlobeNewswire)
Jan-28-23 08:00AM	How Athira and its former CEO are moving on after controversial split (American City Business Journals)
Jan-27-23 10:08AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-17-23 01:00AM	Former Athira CEO on her controversial exit: 'I was relieved that it came to an end' (American City Business Journals)
Jan-05-23 07:00AM	Athira Pharma Provides 2023 Pipeline Outlook (GlobeNewswire)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research) +6.62%
Dec-21-22 07:00AM	Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics (GlobeNewswire)
Dec-09-22 05:34AM	Insider Buying: The Athira Pharma, Inc. (NASDAQ:ATHA) Independent Chairwoman of the Board Just Bought 361% More Shares (Simply Wall St.)
Dec-05-22 07:30AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -10.37%
Dec-01-22 07:00AM	Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 3:30 pm Eastern time (GlobeNewswire)
Nov-29-22 11:00AM	Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimers Disease Patients from ACT-AD Phase 2 Study at CTAD Conference (GlobeNewswire)
Nov-28-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -5.02%
Nov-21-22 07:00AM	Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Nov-16-22 07:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference (GlobeNewswire)
Nov-10-22 04:05PM	Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire) +7.97% +8.39%
Nov-09-22 07:00AM	Athira Pharma to Present at Stifel 2022 Healthcare Conference (GlobeNewswire) -7.07%
Nov-07-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference (GlobeNewswire)
Oct-30-22 08:29AM	Athira Pharma, Inc. (NASDAQ:ATHA) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)
Oct-17-22 07:00AM	Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients Following Independent, Unblinded Interim Analysis (GlobeNewswire) +9.03%
Sep-16-22 08:14AM	Multiple insiders bought Athira Pharma, Inc. (NASDAQ:ATHA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-06-22 03:22PM	Athira Outlines Possible Comeback For Alzheimer's Candidate (Benzinga)
07:00AM	Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients (GlobeNewswire)
Aug-20-22 08:01AM	Athira Pharma (NASDAQ:ATHA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 04:05PM	Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire)

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jun 30 '25	Option Exercise	0.00	36,666	0	177,427	Jul 02 04:35 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jul 01 '25	Sale	0.29	8,526	2,502	168,901	Jul 02 04:35 PM
Litton Mark James	President and CEO	Jun 30 '25	Option Exercise	0.00	108,334	0	350,925	Jul 02 04:34 PM
Litton Mark James	President and CEO	Jul 01 '25	Sale	0.29	25,123	7,374	325,802	Jul 02 04:34 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jun 30 '25	Option Exercise	0.00	46,666	0	82,507	Jul 02 04:33 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	0.29	10,842	3,182	71,665	Jul 02 04:33 PM
Worthington Mark	General Counsel and CCO	Jun 30 '25	Option Exercise	0.00	36,666	0	120,401	Jul 02 04:33 PM
Worthington Mark	General Counsel and CCO	Jul 01 '25	Sale	0.29	8,526	2,502	111,875	Jul 02 04:33 PM
Renninger Robert	SVP, Finance and Accounting	Jun 30 '25	Option Exercise	0.00	12,359	0	112,083	Jul 02 04:32 PM
Renninger Robert	SVP, Finance and Accounting	Jul 01 '25	Sale	0.29	2,897	850	109,186	Jul 02 04:32 PM
Mark James Litton	Officer	Jul 01 '25	Proposed Sale	0.29	25,123	7,374		Jul 01 07:37 PM
Javier San Martin	Officer	Jul 01 '25	Proposed Sale	0.29	10,842	3,182		Jul 01 07:36 PM
Kevin Church	Officer	Jul 01 '25	Proposed Sale	0.29	8,526	2,502		Jul 01 07:34 PM
Mark Worthington	Officer	Jul 01 '25	Proposed Sale	0.29	8,526	2,502		Jul 01 07:33 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Dec 31 '24	Option Exercise	0.00	46,667	0	46,667	Jan 03 05:05 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jan 02 '25	Sale	0.56	10,826	6,083	35,841	Jan 03 05:05 PM
Litton Mark James	President and CEO	Dec 31 '24	Option Exercise	0.00	108,333	0	267,698	Jan 03 05:04 PM
Litton Mark James	President and CEO	Jan 02 '25	Sale	0.56	25,107	14,108	242,591	Jan 03 05:04 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Dec 31 '24	Option Exercise	0.00	36,667	0	139,271	Jan 03 05:03 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jan 02 '25	Sale	0.56	8,510	4,782	130,761	Jan 03 05:03 PM
Renninger Robert	VP of Finance	Dec 31 '24	Option Exercise	0.00	12,359	0	92,605	Jan 03 05:01 PM
Renninger Robert	VP of Finance	Jan 02 '25	Sale	0.56	2,881	1,619	89,724	Jan 03 05:01 PM
Worthington Mark	General Counsel and CCO	Dec 31 '24	Option Exercise	0.00	36,667	0	92,245	Jan 03 05:00 PM
Worthington Mark	General Counsel and CCO	Jan 02 '25	Sale	0.56	8,510	4,782	83,735	Jan 03 05:00 PM
Javier San Martin	Officer	Jan 02 '25	Proposed Sale	0.56	10,826	6,083		Jan 02 08:06 PM
Mark James Litton	Officer	Jan 02 '25	Proposed Sale	0.56	25,107	14,108		Jan 02 08:05 PM
Mark Worthington	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:04 PM
Kevin Church	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:02 PM

LYRA

OBIO

ACRV

ALDX

SLDB

MGTX

ATXS

VRCA

ATHA

Upgrade your FINVIZ experience